Invictus MD Announces Conditional Approval to List on the TSX Venture Exchange
March 27 2017 - 10:55AM
InvestorsHub NewsWire
Invictus MD Announces Conditional Approval to
List on the TSX Venture Exchange
VANCOUVER, BC
-- March 27, 2017 -- InvestorsHub NewsWire -- INVICTUS MD
STRATEGIES CORP. ("Invictus MD" or the
"Company")
(CSE:
IMH;
OTC: IVITF; FRA: 8IS) Invictus MD is pleased to announce it has
received conditional approval to list its common shares for trading
on the TSX Venture Exchange.
Receiving the
conditional listing approval from the TSXV follows a year of
significant achievements for Invictus-MD. Some of which
include:
- The successful test crops at AB
Laboratories Inc. ("AB Labs"), a Licensed
Producer under the Access to Cannabis for Medical Purposes
Regulations ("ACMPR"), currently operating at half capacity, with full
production capacity scheduled by the end of May
2017;
- The 100 acre acquisition by AB Ventures Inc.
("AB Ventures") scheduled to close on May 1, 2017, that once
licensed under the ACMPR, will be used for future cannabis
cultivation with plans to
construct five production facilities on the new land totalling
100,000 square feet;
- Closed the definitive option agreement to acquire 100%
interest in OptionCo., who has constructed a 6,800 square foot
facility with a 30,000 square foot expansion plan floor plate, and
an option to add a mezzanine within the 60,000 square foot secured
perimeter sitting on 150 acres of secured-title land. The large
land package provides sufficient expansion capability to construct
the necessary facilities to meet future demand resulting from the
coming adult recreational use opportunity and capitalizes on some
of the lowest operational costs in the country, such as power and
water. Furthermore, given OptionCo.’s location, the dry air
mitigates the risk of mold and insects. OptionCo. also has plans to
produce extracted or oil based products. Every part of OptionCo.’s
facility design, location, branding and corporate culture, has been
designed to ensure the product of the highest level of quality
medical cannabis is achieved. They have already received great interest in its
products from doctors and clinics. OptionCo. had its pre-license inspection by
Health Canada in early January 2017 and anticipates receiving a
license to cultivate under the ACMPR in short order;
and
- Raised $28.2 million in the past four months and
currently have $15.5 million in cash in the bank after acquiring
33.33% of AB Laboratories Inc., and 100 acres for AB Ventures Inc.
that will support future cannabis cultivation.
"As one of the few
cannabis producing companies in North America listed on a major
exchange such as the TSXV, this move will enable us to engage a
wider investor audience, along with strengthening the cannabis
sector," said Dan Kriznic, Chairman & CEO, Invictus
MD.
About Invictus
MD Strategies Corp.
Invictus MD Strategies
Corp., Canada’s Cannabis Company, is focused on three main
verticals within the burgeoning Canadian cannabis sector: Licensed
Producers under the ACMPR; Fertilizer and Nutrients through Future
Harvest Development Ltd.; and Cannabis Data and Delivery, with its
wholly owned subsidiary Poda Technologies Ltd.
For more information,
please visit www.invictus-md.com.
On Behalf of the
Board,
Dan Kriznic
Chairman &
CEO
604-368-6437
Larry
Heinzlmeir
Vice President,
Marketing & Communications
604-537-8676
CAUTIONARY NOTE
REGARDING FORWARD-LOOKING STATEMENTS: This news release contains
certain "forward-looking statements" within the meaning of such
statements under applicable securities law. Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These statements are only predictions.
Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements
throughout this news release. Forward-looking statements are based
on the opinions and estimates of management at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. There is no assurance that the Proposal
will be completed on the terms or within the timeframe contemplated
in this news release or at all. The Company is under no
obligation, and expressly disclaims any intention or obligation, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
expressly required by applicable law.
Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Mar 2023 to Mar 2024